Melanoma Research Victoria

Source: Cancer Therapy Advisor, April 2019 A 3-center studyusing viral therapy talimogene laherparepvec (TVEC; Imlygic) in advanced melanoma has reported some of the best patient response rates since the drug was approved by the US Food and Drug Administration (FDA) in 2015.1 The research involved patients from Emory University, Atlanta, Georgia; the Moffitt Cancer Center, […]

Read the full story

Source: Healio, March 2019 ATLANTA — The combination of the histone deacetylase inhibitor entinostat and the anti-PD-1 inhibitor pembrolizumab induced clinical responses and appeared well-tolerated among patients with melanoma that progressed on prior anti-PD-1 treatment, according to results from the single-arm ENCORE 601 phase 1b/phase 2 clinical trial presented at American Association of Cancer Research Annual Meeting. […]

Read the full story

Source: Cancer Therapy Advisor, March 2019 Results from a retrospective study showed that most patients with advanced BRAF-mutant melanoma receiving combination therapy with a BRAF and a MEK inhibitor following immune checkpoint blockade required dose modifications, and nearly one-third required hospitalization due to an adverse reaction. BRAK/MEK inhibitor combination therapy and programmed cell death 1 (PD-1) […]

Read the full story

Source: EurekAlert!, March 2019 ATLANTA — A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed clinical responses in patients with melanoma that had progressed on prior anti-PD-1 treatment, according to results from the ENCORE 601 phase Ib/II clinical trial presented at the AACR Annual Meeting 2019, March […]

Read the full story